title: [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
abstract: OBJECTIVE
  Biochemical modulation (BM) was initially used to enhance the effect of 5-fluorouracil (5-FU) by modulating its pharmacological action with the addition of other drugs. BM with low-dose cisplatin and 5-FU or UFT has been examined in cases of advanced gastric or pancreas cancer and 30 to 40% response rates have been reported. In the present study, the effect of BM on hormone refractory prostate cancer (HRPC) patients was examined.
  
  
  METHODS
  BM consisting of 5 mg/body of cisplatin 3 times per week and 300-450 mg of UFT/day was given to 30 HRPC patients (median and range of age: 66 and 52-72, respectively). The ECOG performance status was 0 to 1. Gleason score was 7 in 8 patients, 8 in 10 patients and 9 in 12 patients, respectively. The metastatic site was bone in 29 patients (extent of disease on bone scan [EOD] grade 1: 10, 2: 10, 3: 8, 4: 1), lymph node in 8 and liver in 1.
  
  
  RESULTS
  Among the 29 patients assessable for bone metastasis, 5 (17%) obtained marked improvement on bone scan. One was EOD grade 4 (super bone scan) and 4 were EOD grade 1-3. Eight (28%) were stable and 16 (55%) progressed on bone scan. Among 8 patients with lymph node metastasis, 4 (50%) showed partial response and 4 (50%) progression. One patient with liver metastasis showed complete response. Fourteen (47%) out of 30 patients showed a PSA decline of 50% or greater. Their median response duration was 8 months (range; 2 to 44 months). Among the 25 patients assessable for bone pain, 7 (28%) improved, 12 (48%) remained stable and 6 (24%) progressed. A side effect of Grade II anemia was seen in one patient.
  
  
  CONCLUSIONS
  BM is effective in almost half of hormone refractory prostate cancer patients.
authors.affiliation: Dept. of Urology, Tohoku University School of Medicine.
authors.forename: Senji
authors.initials: S
authors.lastname: Hoshi
authors.forename: Chikara
authors.initials: C
authors.lastname: Ohyama
authors.forename: Shynichi
authors.initials: S
authors.lastname: Namiki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hagisawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Satoh
authors.forename: Seiichi
authors.initials: S
authors.lastname: Saito
authors.forename: Kunio
authors.initials: K
authors.lastname: Ono
authors.forename: Tetuhiko
authors.initials: T
authors.lastname: Shirasaka
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Arai
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil; D002945:Cisplatin